Compare Pfizer Inc (PFE) vs ProShares Ultra QQQ ETF (QLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs ProShares Ultra QQQ ETF — how do they compare? Pfizer Inc trades at $27.75 (market cap $159.59B), while ProShares Ultra QQQ ETF trades at $99.1 (market cap $15.83B). The key difference: Pfizer Inc is far larger — about 10.1× ProShares Ultra QQQ ETF's market cap, and Pfizer Inc pays a 6.14% dividend while ProShares Ultra QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and ProShares Ultra QQQ ETF for 37 Days on average.
| PFE | QLD | |
|---|---|---|
Market Cap | $159.59B | $15.83B |
Volume | 30,937,010 | 3,097,438 |
Sector | Health | Leveraged / Inverse |
52-Week High | $29.02 | $100.77 |
52-Week Low | $23.67 | $57.16 |
Typical Hold Time | 158 Days | 37 Days |
Enterprise Value | $211.09B | — |
Dividend Yield | 6.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
QLD (ProShares Ultra QQQ ETF) trades at $100.23, down 0.54% on the day, with technical indicators showing a bullish moving average signal but overbought RSI conditions. The ETF provides 2x leveraged exposure to the Nasdaq-100 index, offering amplified returns during market rallies while being less volatile than 3x leveraged alternatives. Recent institutional buying activity and media coverage highlight continued investor interest in leveraged tech exposure.
The outlook for QLD remains tied to Nasdaq-100 performance, with technical support at $99 and resistance at $101. While the bullish moving average alignment suggests upward momentum, overbought RSI levels indicate potential near-term consolidation. Key risks include market volatility, Federal Reserve policy impacts, and the inherent leverage decay characteristic of daily reset ETFs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →
